Tumor-specific anti-EGFR antibody and application thereof
The present invention provides a tumor-specific anti-EGFR antibody and application thereof. The antibody can be used for preparing targeted antitumor drugs and tumor diagnosis drugs.
1. A monoclonal antibody specifically recognizing EGFRvIII expressed or EGFR overexpressed by tumor cells, wherein the antibody comprises:
antibody (a), wherein the light chain variable region thereof has CDR1 of SEQ ID NO: 41, CDR2 of SEQ ID NO: 42, and CDR3 of SEQ ID NO: 43, and the heavy chain variable region thereof has CDR1 of SEQ ID NO: 44, CDR2 of SEQ ID NO: 45, and CDR3 of SEQ ID NO: 46;
antibody (b), wherein the light chain variable region thereof has CDR1 of SEQ ID NO: 47, CDR2 of SEQ ID NO: 42, and CDR3 of SEQ ID NO: 48, and the heavy chain variable region thereof has CDR1 of SEQ ID NO: 44, CDR2 of SEQ ID NO: 49, and CDR3 of SEQ ID NO: 50;
antibody (c), wherein the light chain variable region thereof has CDR1 of SEQ ID NO: 41, CDR2 of SEQ ID NO: 42, and CDR3 of SEQ ID NO: 48, and the heavy chain variable region thereof has CDR1 of SEQ ID NO: 44, CDR2 of SEQ ID NO: 51, and CDR3 of SEQ ID NO: 50;
antibody (d), wherein the light chain variable region thereof has CDR1 of SEQ ID NO: 41, CDR2 of SEQ ID NO: 42, and CDR3 of SEQ ID NO: 43, and the heavy chain variable region thereof has CDR1 of SEQ ID NO: 44, CDR2 of SEQ ID NO: 52, and CDR3 of SEQ ID NO: 50;
antibody (e), wherein the light chain variable region thereof has CDR1 of SEQ ID NO: 41, CDR2 of SEQ ID NO: 42, and CDR3 of SEQ ID NO: 43, and the heavy chain variable region thereof has CDR1 of SEQ ID NO: 44, CDR2 of SEQ ID NO: 45, and CDR3 of SEQ ID NO: 50;
antibody (f), wherein light chain variable region thereof has CDR1 of SEQ ID NO: 41, CDR2 of SEQ ID NO: 53, and CDR3 of SEQ ID NO: 54, and the heavy chain variable region thereof has CDR1 of SEQ ID NO: 44, CDR2 of SEQ ID NO: 51, and CDR3 of SEQ ID NO: 50;
antibody (g), wherein the light chain variable region has CDR1 of SEQ ID NO: 41, CDR2 of SEQ ID NO: 42, and CDR3 of SEQ ID NO: 54, and the heavy chain variable region thereof has CDR1 of SEQ ID NO: 44, CDR2 of SEQ ID NO: 51, and CDR3 of SEQ ID NO: 50;
antibody (h), wherein the light chain variable region thereof has CDR1 of SEQ ID NO: 55, CDR2 of SEQ ID NO: 42, and CDR3 of SEQ ID NO: 56, and the heavy chain variable region thereof has CDR1 of SEQ ID NO: 44, CDR2 of SEQ ID NO: 45, and CDR3 of SEQ ID NO: 50;
antibody (i), wherein the light chain variable region thereof has CDR1 of SEQ ID NO: 41, CDR2 of SEQ ID NO: 53, and CDR3 of SEQ ID NO: 56, and the heavy chain variable region thereof has CDR1 of SEQ ID NO: 44, CDR2 of SEQ ID NO: 52, and CDR3 of SEQ ID NO: 50;
antibody (j), wherein the light chain variable region thereof has CDR1 of SEQ ID NO: 41, CDR2 of SEQ ID NO: 42, and CDR3 of SEQ ID NO: 56, and the heavy chain variable region thereof has CDR1 of SEQ ID NO: 44, CDR2 of SEQ ID NO: 52, and CDR3 of SEQ ID NO: 50; or
antibody (k), wherein the light chain variable region thereof has CDR1 of SEQ ID NO: 41, CDR2 of SEQ ID NO: 42, and CDR3 of SEQ ID NO: 57, and the heavy chain variable region thereof has CDR1 of SEQ ID NO: 44, CDR2 of SEQ ID NO: 52, and CDR3 of SEQ ID NO: 50.
2. The antibody of claim 1 , wherein the amino acid sequence of the heavy chain variable region of the antibody is shown in positions 124 to 239 of SEQ ID NO: 13, and the amino acid sequence of the light chain variable region of the antibody is shown in positions 1-108 of SEQ ID NO: 13;
the amino acid sequence of the heavy chain variable region of the antibody is shown in positions 124 to 239 of SEQ ID NO: 59, and the amino acid sequence of the light chain variable region of the antibody is shown in positions 1-108 of SEQ ID NO: 59;
the amino acid sequence of the heavy chain variable region of the antibody is shown in positions 124 to 239 of SEQ ID NO: 61, and the amino acid sequence of the light chain variable region of the antibody is shown in positions 1-108 of SEQ ID NO: 61;
the amino acid sequence of the heavy chain variable region of the antibody is shown in positions 124 to 239 of SEQ ID NO: 63, and the amino acid sequence of the light chain variable region of the antibody is shown in positions 1-108 of SEQ ID NO: 63;
the amino acid sequence of the heavy chain variable region of the antibody is shown in positions 124 to 239 of SEQ ID NO: 65, and the amino acid sequence of the light chain variable region of the antibody is shown in positions 1-108 of SEQ ID NO: 65;
the amino acid sequence of the heavy chain variable region of the antibody is shown in positions 124 to 239 of SEQ ID NO: 67, and the amino acid sequence of the light chain variable region of the antibody is shown in positions 1-108 of SEQ ID NO: 67;
the amino acid sequence of the heavy chain variable region of the antibody is shown in positions 124 to 239 of SEQ ID NO: 69, and the amino acid sequence of the light chain variable region of the antibody is shown in positions 1-108 of SEQ ID NO: 69;
the amino acid sequence of the heavy chain variable region of the antibody is shown in positions 124 to 239 of SEQ ID NO: 71, and the amino acid sequence of the light chain variable region of the antibody is shown in positions 1-108 of SEQ ID NO: 71;
the amino acid sequence of the heavy chain variable region of the antibody is shown in positions 124 to 239 of SEQ ID NO: 73, and the amino acid sequence of the light chain variable region of the antibody is shown in positions 1-108 of SEQ ID NO: 73;
the amino acid sequence of the heavy chain variable region of the antibody is shown in positions 124 to 239 of SEQ ID NO: 75, and the amino acid sequence of the light chain variable region of the antibody is shown in positions 1-108 of SEQ ID NO: 75; or
the amino acid sequence of the heavy chain variable region of the antibody is shown in positions 124 to 239 of SEQ ID NO: 77, and the amino acid sequence of the light chain variable region of the antibody is shown in positions 1-108 of SEQ ID NO: 77.
3. The antibody of claim 1 , wherein the antibody is the antibody (a).
4. The antibody of claim 3 , wherein the heavy chain variable region of the antibody comprises the amino acid sequence shown in positions 124 to 239 of SEQ ID NO: 13, and light chain variable region of the antibody comprises the amino acid sequence shown in positions 1-108 of SEQ ID NO: 13.
5. A pharmaceutical composition comprising the antibody of claim 1 and a pharmaceutical acceptable excipient.